Study of NaQuinate in Healthy Volunteers

Osteoporosis Clinical Trial

Official title:

A Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of NaQuinate in Healthy Volunteers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04036617
• Other study ID #: HML-1/01/001
• Status: Recruiting
• Phase: Phase 1
• Start date: June 18, 2019
• Est. completion date: May 30, 2020

Study information

• Verified date: July 2019
• Source: Haoma Medica Limited
• Contact: julia m tilson
• Phone: +44 (0)7725 844778
• Email: julia.tilson[@]haomamedica.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase 1, randomised, double-blind, placebo-controlled study of NaQuinate in healthy subjects after single ascending oral (PO) doses and multiple ascending PO doses.

Description:

This first-in-human (FIH) clinical study is a Phase 1, randomised, double-blind, placebo-controlled study to assess the safety, tolerability, and PK of NaQuinate in healthy subjects after single ascending oral (PO) doses and multiple ascending PO doses.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 58
• Est. completion date: May 30, 2020
• Est. primary completion date: December 31, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Subjects who meet the following criteria will be considered eligible to participate in the clinical study:

1. Healthy male and female subjects (women of non-childbearing potential) between 18 and 55 years of age. Note: Women of non-childbearing potential is defined as being amenorrhoeic for >12 months with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms). However, if indicated, this should be confirmed by follicle-stimulation hormone (FSH) levels consistent with menopause (according to local laboratory ranges). Or, have been permanently sterilised (e.g. hysterectomy, bilateral salpingectomy or bilateral oophorectomy).

2. The subject is healthy as determined by past medical history and as judged by the PI or designee.

3. The subject voluntarily agrees to participate in this study and signs an Independent Ethics Committee (IEC)-approved informed consent prior to performing any of the Screening procedures.

4. The subject has a BMI of 18-32 kg/m2, inclusive, at Screening.

5. The subject has no clinically significant history of previous allergy or sensitivity to NaQuinate or any of the excipients contained within the IMP.

6. The subject has no clinically significant abnormal serum biochemistry, haematology, coagulation and urine examination values within 28 days before the first dose of IMP.

7. The subject has no clinically significant abnormalities in 12-lead electrocardiogram (QTcF = 450 mSec and PR 120-220 mSec).

8. Male subjects and their female spouse/partner of childbearing potential must use appropriate effective methods of contraception from the time of dosing until after the end-of-study (EOS) visit. See Section 7.5.2 for protocol-specified contraception guidance.

9. Male subjects must not donate sperm from first dose until at least 3 months after last dose of IMP.

10. The subject is a non-smoker, defined as a subject who has not smoked previously and/or who has discontinued smoking or the use of nicotine/nicotine-containing products (including snuff and similar products) at least 3 months before the Screening visit.

11. The subject must be available to complete the study (including all Follow-up visits).

12. The subject must satisfy the PI / designee about their fitness to participate in the study and agree to comply with the protocol requirements, instructions, and study related restrictions

Exclusion Criteria:

• Subjects who meet one or more of the following criteria will not be considered eligible to participate in the clinical study:

1. Female subjects who are breastfeeding or female subjects with a positive serum pregnancy test at Screening or a positive urine pregnancy test on Day -1.

2. Subjects who have donated blood in the 3 months prior to Screening, plasma in the 7 days prior to Screening or platelets in the 6 weeks prior to Screening.

3. A positive urine cotinine result at Screening or on Day -1.

4. Subjects who have used the following within 7 days of first dosing: any non-prescribed systemic or topical medication (with the exception of paracetamol to a maximum of 2 g per day), remedy or supplement, any prescribed systemic or topical medication within 14 days of first dosing.

5. Subjects who have clinically significant abnormalities in vital signs including:

Systolic BP < 90 mmHG or > 140 mmHg; Diastolic BP < 50 mmHG or > 90 mmHG; Pulse rate < 45 or > 90 beats per minute.

6. Subjects who have a history of significant drug allergy (e.g., anaphylaxis) or any clinically significant allergic condition (excluding hay fever), as determined by the PI.

7. Any clinically significant abnormal haematology results, as determined by the PI.

8. Subjects who have a confirmed positive urine drugs of abuse screen at Screening or Day -1, or a confirmed positive urine alcohol test at Screening or Day -1 (N.B. a positive alcohol result may be repeated at the Investigator's discretion) or subjects who are unwilling to avoid the use of alcohol within 48 hours before any study visit and while confined to the clinical unit.

9. Subjects who received last IMP dose in a clinical study within the following time period prior to dosing: 3 months or 5 half-lives, whichever is longer.

10. Subjects who have had a clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of dosing, as determined by the PI.

11. A positive serology test for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, or antibodies to human immunodeficiency virus type 1 (HIV-1) and/or type 2 (HIV 2) at Screening.

12. Vulnerable subjects defined as individuals whose willingness to volunteer in a clinical study may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate (e.g., persons in detention, minors and those incapable of giving consent).

Related Conditions & MeSH terms

• Osteoporosis

Intervention

Drug:
• NaQuinate
SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150mg
• Placebo
SAD cohorts will receive 1 dose of placebo between 10-150 mg. MAD cohorts will receive 7 days dosing of placebo between 70-150mg

Locations

Country	Name	City	State
United Kingdom	Parexel Early Phase Clinical Unit - London	London

Sponsors (2)

Lead Sponsor	Collaborator
Haoma Medica Limited	Parexel

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To investigate the safety by assessment of AEs, of NaQuinate in healthy volunteers	safety of single and multiple doses of NaQuinate as assess by the number of participants with treatment-related adverse events evaluated by the PI for their intensity, causality and severity, including Adverse events of Special interest.	approximately 8 weeks
Primary	To investigate the tolerability by assessment of AEs, of NaQuinate in healthy volunteers	tolerability of single and multiple doses of NaQuinate as assess by the number of participants with treatment-related adverse events evaluated by the PI for their intensity, causality and severity, including Adverse events of Special interest.	approximately 8 weeks
Secondary	to Investigate the pharmacokinetics by measurment of Cmax of exposure to NaQuinate in healthy volunteers	PK parameters after single or multiple dose administration measured by Cmax of exposure to NaQuninate in healthy volunteers	approximately 8 weeks